ArticleThe New England journal of medicine2016
Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer.
Article in The New England journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Perspectives on the gut microbiota in patients with non-small cell lung cancer-Two-Sample Mendelian Randomization combined with bibliometric analysis (2001-2023).Journal of cardiothoracic surgery · 2025Review
- Inflammatory parameters in NSCLC with driver mutation.Lung cancer management · 2024Article
- Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional study.Scientific reports · 2023Article
- Fusing WGCNA and Machine Learning for Immune-Related Gene Prognostic Index in Lung Adenocarcinoma: Precision Prognosis, Tumor Microenvironment Profiling, and Biomarker Discovery.Journal of inflammation research · 2023Article
- The metastatic niche formation: focus on extracellular vesicle-mediated dialogue between lung cancer cells and the microenvironment.Frontiers in oncology · 2023Review
- Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.Frontiers in immunology · 2022Article
- Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.Cancer immunology, immunotherapy : CII · 2021Article
- Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.BMC cancer · 2021Article
- Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity.Molecular cancer therapeutics · 2021Article
- Complete metabolic response in patients with advanced nonsmall cell lung cancer with prolonged response to immune checkpoint inhibitor therapy.Journal for immunotherapy of cancer · 2021Article
- Strategies for the Construction of Mouse Models With Humanized Immune System and Evaluation of Tumor Immune Checkpoint Inhibitor Therapy.Frontiers in oncology · 2021Review
- Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer.Annals of translational medicine · 2020Article
- Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.Annals of oncology : official journal of the European Society for Medical Oncology · 2019Article
- Liquid biopsy for lung cancer immunotherapy.Oncology letters · 2019Review
- The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies.Molecular imaging and biology · 2018Review
- Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center.Medical oncology (Northwood, London, England) · 2018Article
- Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.Journal of thoracic disease · 2017Article
- Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Article
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26840144What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.